Aims/hypothesis A strategy to enhance pancreatic islet functional beta cell mass (BCM) while restraining inflammation, through the manipulation of molecular and cellular targets, would provide a means to counteract the deteriorating glycaemic control associated with diabetes mellitus. The aims of the current study were to investigate the therapeutic potential of such a target, the islet-enriched and diabeteslinked transcription factor paired box 4 (PAX4), to restrain experimental autoimmune diabetes (EAD) in the RIP-B7.1 mouse model background and to characterise putative cellular mechanisms associated with preserved BCM. Methods Two groups of RIP-B7.1 mice were genetically engineered to: (1) conditionally express either PAX4 (BPTL) or its diabetes-linked mutant variant R129W (mutBPTL) using doxycycline (DOX); and (2) constitutively express luciferase in beta cells through the use of RIP. Mice were treated or not with DOX, and EAD was induced by immunisation with a murine preproinsulin II cDNA expression plasmid. The development of hyperglycaemia was monitored for up to 4 weeks following immunisation and alterations in the BCM were assessed weekly by noninvasive in vivo bioluminescence intensity (BLI). In parallel, BCM, islet cell proliferation and apoptosis were evaluated by immunocytochemistry. Alterations in PAX4-and PAX4R129W-mediated islet gene expression were investigated by microarray profiling. PAX4 preservation of endoplasmic reticulum (ER) homeostasis was assessed using thapsigargin, electron microscopy and intracellular calcium measurements.
Introduction
The islet of Langerhans is the core unit of the endocrine pancreas, which regulates blood glucose homeostasis. Regulation is achieved by the release of insulin from beta cells in response to increasing levels of glucose and by the secretion of glucagon from alpha cells under fasting conditions. Imbalance in this circuitry leads to either hyperglycaemia, the hallmark of diabetes mellitus, or hypoglycaemia. Loss of beta cell function coupled to insulin resistance of target tissues, which usually associates with obesity and chronic low-grade inflammation, defines type 2 diabetes [1] ; high-grade T lymphocyte inflammation mediating autoimmune beta cell destruction is characteristic of type 1 diabetes [2] .
Emerging evidence suggests that alterations in endoplasmic reticulum (ER) function contribute to beta cell disarray in both type 1 and 2 diabetes [3] . In an attempt to restore ER function and prevent apoptosis, cells activate the unfolded protein response (UPR) [4] . The crucial role of the UPR in balancing beta cell death and survival is illustrated in the human Wolfram and Wolcott-Rallison syndromes, in which mutations in UPR genes result in unresolved ER stress, beta cell death and early-onset diabetes [5, 6] . Interestingly, MODY genes such as Pdx1 and Hnf1a regulate UPR-associated genes [7, 8] . These clinical conditions suggest that islet-enriched transcription factors involved in insulin biosynthesis and secretion also preserve the BCM by limiting ER stress. Paired box (Pax) genes encode transcription factors critical for tissue development and cellular differentiation [9] . Paired box 4 (PAX4) is necessary for the generation of pancreatic islet cell progenitors and their differentiation towards beta cells [10, 11] . Pax4 gene mutations have been associated with type 1 and 2 diabetes as well as with ketosis-prone diabetes, suggesting a key role of PAX4 in mature islets [12, 13] . Accordingly, overexpression of PAX4 in adult beta cells was shown to block streptozotocin (STZ)-induced hyperglycaemia in mice whereas the diabetes-linked variant PAX4R129W was less efficient [14] . Despite differences in nitric oxide synthase 2 (NOS2) levels, both PAX4-and PAX4R129W-expressing islets exhibited similar levels of cytokine-induced NO production, indicating that the nuclear factor-κB (NF-κB) signalling pathway was fully activated and that additional anti-apoptotic pathways are involved in islet survival. Consistent with this premise, PAX4 islets expressed higher levels of B cell CLL/ lymphoma 2 (BCL-2) [14] . Nonetheless, overexpression of BCL-2 in islets did not prevent autoimmune-mediated beta cell destruction and development of hyperglycaemia [15] . Thus, although these data highlight the protective function of PAX4 against a chemical acute stress, whether such an effect can also be conveyed in the context of a pathophysiological autoimmune attack and the molecular mechanism involved in this protection remain to be established.
Herein, we investigated whether PAX4 and PAX4R129W could promote beta cell health, preventing the development of hyperglycaemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes (EAD), and sought to characterise the PAX4-regulated pathways implicated in islet survival and expansion.
Methods
Animals and bioluminescence imaging Mouse experiments were approved by the local ethics committee and performed according to the Spanish law on animal use RD 53/2013. The rationale for using RIP-B7.1 (kindly supplied by B. O. Boehm) rather than NOD mice for the current study is provided in the electronic supplementary material (ESM) Methods. BPTL mice were derived as outlined in Fig. 1a , b and maintained on a C57bl/6 background. This mouse harbours four transgenes: (1) RIP-B7.1, a construct coding for the Cd80 gene under control of the rat insulin promoter (RIP); (2) the tetracycline response element (TRE)/ cytomegalo mosaic virus (CMV) Pax4, a tetracyclineinducible CMV promoter driving Pax4 expression; (3) the RIP-reverse tetracycline trans-activator (rtTA), a construct allowing selective expression of Pax4 in beta cells exposed to DOX; and (4) the MIP-Luciferase (Luc), a construct that expresses luciferase under the mouse insulin promoter (MIP), allowing assessment of BCM using non-invasive in vivo imaging technology. Induction of Pax4 or Pax4R129W gene expression using doxycycline (DOX) was performed as previously described [14] , while EAD was achieved by i.m. immunisation of 9-week-old BPTL animals with 50 μg of pC1/ppins plasmid DNA (1 μg/μl) encoding the murine preproinsulin II. Blood glucose levels were measured using a Precision Xceed glucometer (Abbott, Madrid, Spain). Bioluminescence imaging was performed using a Xenogen IVIS 50 imaging system as previously described [16] .
Islet isolation and treatment Islets were isolated and cultured as previously described [14] . Total RNA was extracted using the RNeasy Micro Kit (Qiagen, Madrid, Spain) and quantitative (q)-PCR was performed as described previously [17] . Primer sequences can be obtained on request. For studies on thapsigargin-induced ER stress and apoptosis, islets from either Pax4/rtTA or Pax4R129W/rtTA transgenic mice were treated with 1 μg/l DOX for 96 h or left untreated [14] . Fluorescence of the Discosoma sp. red fluorescent protein (DsRed) correlating with Pax4 or Pax4R129W expression was monitored using an ImageXpress Micro System (Molecular Devices, Wokingham, UK). Islets were then treated or not with 1 μmol/l thapsigargin for 48 h and apoptosis was assessed by ELISA (Roche Diagnostics, Mannheim, Germany). Glucose-stimulated insulin secretion (GSIS) was performed as previously described [18] .
Intracellular Ca 2+ measurements Isolated islets were incubated for 1 h at room temperature with 2 μmol/l Fura-2 (Qiagen). Fluorescence recordings were performed using an inverted epifluorescence microscope (Axiovert 200; Zeiss, Jena, Germany) equipped with 360 nm and 380 nm bandpass filters. Recordings were expressed as the ratio of fluorescence at 360 nm and 380 nm (F360/380). Images were taken every 3 s. Intracellular [Ca 2+ ] changes in response to stimuli were analysed as previously described [19] . MIN6 cell culture and RNA interference MIN6 cells were cultured as previously described [20] and transfected with either 50 μmol Pax4 small interfering (si)RNA (Sigma) or scramble siRNA using Oligofectamine (Life Technologies, Madrid, Spain). Cells were either processed for RNA or treated with thapsigargin (Sigma-Aldrich, Madrid, Spain) to assess apoptosis 48 h after transfection.
Immunohistochemistry and electron microscopy Dissected pancreases were fixed in 4% paraformaldehyde and processed at the Histology Core Facility, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER). A detailed immunocytochemistry protocol along with the list of antibodies used is provided in ESM Methods and ESM Table 1 . Validation of antibodies was performed on appropriate control samples. The BCM and islet cell number were assessed as described elsewhere [21] . Apoptosis, proliferation and DNA damage were quantified by counting caspase-3-, Ki67-and p53BP1-positive cells, respectively, in at least 20 to 50 islets from three independent pancreatic sections from 3-4 mice per group. Insulitis scoring was performed as previously outlined [22] . For electron microscopy (EM), pancreatic islets were processed using a standard Spurr protocol [23] . Images were acquired with an electron-multiplying charge-coupled device (EMCCD) camera (TRS 2 k × 2 k).
RNA microarray Labelled cRNA samples were prepared from pools of at least 100 islets isolated from either Pax4/ rtTA or Pax4R121W/rtTA transgenic animals (8-week-old females) treated with DOX or not treated [14] . Three preparations of cRNA per group were then hybridised to the GeneChip Mouse Gene 1.0 ST Array chip (Affymetrix, Santa Clara, CA, USA) using the standard protocols of the Genomic Core Facility, CABIMER. Raw data are accessible in the Gene Expression Omnibus database under accession number GSE62846, while its analysis is described in ESM Methods.
Statistical analysis Results are expressed as mean ± SEM. Statistical differences between two conditions were estimated using the unpaired Student's t test. One-way ANOVA was used for comparison of more than two groups with Bonferroni post hoc test or non-parametric Mann-Whitney test (*p < 0.05 and **p < 0.01).
Results

PAX4 expression blunts EAD in immunised BPTL mice
We first monitored in vivo the bioluminescence intensity (BLI) emitted by beta cells of BPTL mice from 4 to 65 weeks of age ( Fig. 1c ). In 4-week-old mice, the bioluminescence signal was two fold higher in male mice than females. Consistent with a transient wave of beta cell apoptosis and decreased rate of islet growth around weaning [24] , both sexes displayed a decline in BLI signal between the fourth and the ninth week ( Fig. 1c ). Thereafter, this signal did not significantly change with age ( Fig. 1c ). Morphometric evaluation revealed that the volume density of beta cells was similar in animals aged from 4 to 16 weeks ( Fig. 1d ). Thus, by 9 weeks of age the bioluminescent signal reflects the mass and function of beta cells, which we hereafter refer to as the functional beta cell mass (BCM). Similar to the RIP-B7.1 animal, immunised BPTL mice developed hyperglycaemia within 21 days ( Fig. 1e ) due to a gradual loss of beta cells (Fig. 1f ), whereas non-immunised mice remained normoglycaemic ( Fig. 1e, f ). We next determined whether PAX4 expression could prevent EAD. Five-week-old BPTL mice were treated with DOX for 4 weeks prior to immunisation. Compared with control mice, islets from treated mice revealed a ten fold increase in Pax4 expression ( Fig. 2a ), but no change in Cd80 transcript levels ( Fig. 2b ). DOX treatment did not alter the BCM or GSIS of PAX4-expressing islets ( Fig. 2c, d ). Nine-week-old untreated controls remained normoglycaemic and featured no variation in bioluminescent signal for up to 28 days ( Fig. 2e ). Immunised BPTL mice without DOX revealed a rapid decrease in BLI, reaching undetectable levels by day 28 post-immunisation, which coincided with sustained hyperglycaemia (Fig. 2f ). Escalation in blood glucose level observed 21 days after immunisation correlated with a 60% decrease in BLI. DOX-treated and immunised BPTL mice maintained both normoglycaemia and bioluminescent signal ( Fig. 2g ). Protection was extended up to 63 days ( Fig. 2h ), at which point 65% of immunised and DOX-treated BPTL mice developed hyperglycaemia, probably because of the robust immune attack conveyed by CD80 overexpression. Immunised and DOX-treated RIP-B7.1 mice developed hyperglycaemia (ESM Fig. 1 ), excluding a protective effect mediated by the antibiotic through alteration in the gut microbiome [25, 26] . Non-DOX-treated BPTL mice suffered a 40% and 80% reduction in the functional BCM after 21 and 28 days of immunisation, respectively. Such changes were not observed in DOX-treated mice (Fig. 3a, b ). By day 63, the latter animals retained approximately 50% of the functional BCM (Fig. 3b ).
PAX4 improves beta cell health and mitigates the autoimmune attack Insulitis assessment at 28 days after immunisation revealed that 65% of islets of DOX-treated BPTL mice were insulitis free (grade 0), whereas 90% of islets derived from non-DOX-treated BPTL mice displayed severe insulitis (grades 2-4) ( Fig. 4a ). Even at 63 days after immunisation only 50% of islets from DOX-treated BPLT mice displayed mild insulitis (Fig. 4a ). DOX treatment also diminished the percentage of cleaved CASPASE-3-positive islet cells in immunised animals ( Fig. 4b and ESM Fig. 2a ). DNA damage induced by NO and reactive oxygen species (ROS) contributes to beta cell death [27, 28] . Immunostaining for the double-strand DNA break marker p53BP1 revealed that PAX4 overexpression reduced DNA damage in islets from either immunised BPTL or STZ-treated mice (Fig. 4c ). These changes were paralleled by increased cell proliferation in DOX-treated BPLT islets ( Fig. 4d and ESM Fig. 2b ).
PAX4 regulates genes important for beta cell proliferation and ER homeostasis Transcriptome profiling was conducted on PAX4 and PAX4R129W islets to highlight PAX4 target genes involved in beta cell health, and those altered by the diabetes-linked mutant variant R129W. We initially demonstrated that DOX-treated and immunised mutBPTL mice developed hyperglycaemia ( Fig. 5a) with an incidence of approximately 75% by day 28 compared with 100% in non-DOX-treated immunised animals (Fig. 5b) . Transcriptome analysis revealed that 770 transcripts were upregulated and 449 were downregulated in PAX4 islets, whereas 1437 genes were upregulated and 1136 downregulated in PAX4R129W islets. Genes showing the largest changes are listed in ESM Table 2 . Notwithstanding this list, we substantiated by qPCR our previous findings [14] that Mafa transcript levels were repressed whereas Nos2 levels were unchanged in PAX4 islets (ESM Fig. 3 ). However, Bcl2 levels were not increased in PAX4-overexpressing islets (ESM Fig. 3 ), arguing against a role of this factor in protecting from EAD [15] .
A functional enrichment analysis disclosed that the cell cycle and the protein processing in ER pathways were among the top upregulated Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways in islets overexpressing PAX4, but were among the most significantly downregulated pathways in islets overexpressing PAX4R129W (adjusted p values < 0.05) (Fig. 5c, d and ESM Tables 3  and 4 ). To contrast the expression levels of genes contributing to these pathways, we generated heat maps amenable to statistical analysis (raw p value < 0.05). Several genes associated with cell cycle were increased in PAX4 islets, while remaining unchanged or having lower levels in islets expressing PAX4R129W (Fig. 5e ). Genes encoding proteins for peptide folding (Hspa5 [also known as Bip], Calr), ER-Golgi translocation (Lman1, Lman2, Sec23b and Plaa) and ER-associated protein degradation (ERAD) (Ufd1l, Derl3, Pdia4, Ssr3, Syvn1 and Dnaja2/Hsp40) were upregulated after overexpression of PAX4, but were downregulated after overexpression of PAX4R129W (Fig. 5f ). The UPR-associated genes Mbtps2, Eif2ak3 and Mapk10 were upregulated in PAX4 islets and were marginally altered in PAX4R129W islets (Fig. 5f ).
PAX4 targets ER integrity and calcium homeostasis, protecting cells against apoptosis
Given that PAX4 but not PAX4R129W targets genes that are involved in ER homeostasis, we investigated the contribution of ER to PAX4-mediated beta cell health. We initially assessed expression levels of calreticulin (Calr), a major Ca 2+ binding protein of the ER lumen and of galectin-9 (Lgals9), a protein involved in immune modulation. Although Pax4 and Pax4R129W transcript levels were increased three fold, Calr and Lgals9 expression levels were only increased in PAX4 islets (Fig. 6a, b ). As Ca 2+ handling by the ER affects the cell sensitivity to apoptosis, we assessed whether PAX4 and PAX4R129W could protect against ER-stress-induced beta cell apoptosis. Islets treated in vitro with DOX exhibited DsRed fluorescence, confirming the expression of the transgenes (Fig. 6c ). Thapsigargin exposure prompted a two fold increase in apoptosis in control mice (Fig. 6d ). DOX reduced both basal and thapsigargin-induced apoptosis only in PAX4 islets (Fig. 6d ). However, Pax4 siRNA-mediated repression in MIN6 cells caused a 60% decrease in Calr transcript levels, with a concomitant sensitisation to thapsigargin-induced apoptosis compared with siControl and thapsigargin-treated cells (Fig. 6e, f) . Perturbation in beta cell ER homeostasis has been linked to ER dilation [29, 30] . Accordingly, islets from non-DOXtreated Pax4 transgenic mice exposed in vitro to thapsigargin displayed distension and fragmentation of the rough ER (RER) in beta cells, an effect prevented by PAX4 overexpression ( Fig. 7) . ER calcium release in response to carbachol was then measured. Calcium release in PAX4-overexpressing beta cells from isolated islets was marginally higher than that of controls cells (Fig. 8a-d) . As the higher ER-Ca 2+ -buffering capacity induced by PAX4 could mask the carbacholstimulated calcium release, we measured cytosolic Ca 2+ signals in response to glucose. Glucose-induced calcium oscillations were improved in isolated islets overexpressing PAX4 compared with control islets (Fig. 8e, f) . The overall Ca 2+ signal was also higher in PAX4-overexpressing cells (Fig. 8g-i) . Thus, PAX4 overexpression leads to improve ER and Ca 2+ homeostasis in the face of beta cell stress as encountered during the islet isolation procedure or an immune attack.
Discussion
Inflammation is a common denominator in types 1 and 2 diabetes, and leads to beta cell failure and death, predominantly by apoptosis. As yet, there is no 'unifying hypothesis' for the mechanisms triggering beta cell deterioration [31, 32] ; deciphering the molecular roadmap regulated by factors such (e, f) Heat maps displaying t statistic values of (e) cell cycle and (f) protein processing in the ER KEGG pathway genes modulated in either PAX4 or PAX4R129W islets vs control. Colours display the t statistic values for all genes within the corresponding KEGG pathway, estimated using the t statistic value from differential expression analysis. GPI, glycosylphosphatidylinositol as PAX4-mutations in which are linked to both forms of diabetes-may help identify common pathways. Herein, we provide proof-of-concept that PAX4, but not PAX4R129W, preserves the BCM and delays the development of hyperglycaemia in the RIP-B7.1 mouse model of EAD. This highlights the mechanistic differences between the wild type and mutant variant. Consistent with previous reports exploiting the RIP-B7.1 model, 90-100% of immunised non-DOX-treated RIP-B7.1 mice bearing either the Pax4 or Pax4R129W transgene developed hyperglycaemia within 3 weeks, correlating with insulitis and beta cell destruction [33] . D O X -m e d i a t e d i n d u c t i o n o f P a x 4 p r e v e n t e d hyperglycaemia development in BPTL animals up to 4 weeks after immunisation, whereas Pax4R129W induction partially reduced the hyperglycaemic incidence in mutBPTL mice. Thus, PAX4 blunts hyperglycaemia in an autoimmune context, in contrast to several other factors such as caspase-3-generated RAS p21 protein activator 1 (RasGAP) N-terminal fragment (fragment N), cytokine response modifier A (CRMA) or BCL-2 which, d e s p i t e i n c r e a s i n g B C M , c o u l d n o t p r e v e n t hyperglycaemia in animal models of type 1 diabetes [15, 22, 34] . Our data imply that in addition to inhibiting apoptosis, PAX4 is involved in additional regulatory pathways, possibly including immune modulation. Correspondingly, insulitis was reduced after PAX4 overexpression, an effect not attributable to a non-specific repression of the Cd80 transgene that facilitates the immune response. Our observations extend the analogous findings that inhibition of vascular endothelial growth factor receptor 2 (VEGFR-2) in NOD mice reversed hyperglycaemia by abrogating insulitis and restoring islet cell function Fig. 7 ER integrity is preserved in PAX4-overexpressing islets. Two sets (upper and lower) of beta cell micrographs from islets isolated from PAX4 transgenic mice, treated with DOX or not treated, and challenged with 1 μmol/l thapsigargin or not challenged. Arrows indicate the RER. Inset is enlarged below each image. Scale bar, 0.5 μm. N, nucleus; V, insulin vesicles [35] . Although the mechanism by which PAX4 acts at the interface of beta cells and the immune system to blunt insulitis and improve islet recovery remains undefined, our genetic analysis revealed that Lgals9 was specifically upregulated in PAX4 islets. This gene induces apoptosis of differentiated T helper 1 (Th1) cells [36] , and its overexpression in NOD mice reduced insulitis and hyperglycaemia [37] , prolonging the survival of grafts [38] . It is therefore plausible that, by enhancing Lgals9 expression, PAX4 may downregulate Th1 function, partially impeding insulitis and improving islet survival.
Transcriptome profiling revealed that cell-cycle-associated genes upregulated by PAX4 were downregulated by PAX4R129W, despite comparable expression levels of both transgenes. Specifically, the type 2 diabetes-associated cyclindependent kinase inhibitor 2A, which strongly inhibits the proliferative cyclin-dependent kinase 4 (CDK4) [39] , was enriched in PAX4R129W islets whereas it was decreased in PAX4 islets. Reciprocally, cyclin D3, which promotes beta cell survival, was increased in PAX4-but not in PAX4R129W-overexpressing islets [40] . These findings provide some molecular insights into the pathogenic effect of the R129W mutation on beta cell plasticity.
Our data also reveal that PAX4, but not PAX4R129W, is a key regulator of ER function by a combined targeting of genes involved in UPR, Ca 2+ homeostasis, ER-Golgi translocation, and ERAD. The functional importance of the transcriptional changes in these genes was validated by the capacity of PAX4 to prevent thapsigargin-induced ER ultrastructural abnormalities and apoptosis of beta cells, consistent with the finding that PAX4-binding sites are enriched within the promoter region of palmitatemodified ER stress response genes [41] . In contrast, repression of PAX4-sensitised MIN6 cells to thapsigargin cell death correlates with reduced CALR levels. Calreticulin is a Ca 2+ chaperone of the ER, which contributes to the quality control of protein folding [42] . Overexpression of CALR in MIN6 cells enhances ER Ca 2+ stores and prevents NO-induced apoptosis [43] . In this context, the production of NO and ROS induced by inflammatory cytokines in the diabetic environment promotes beta cell death by a variety of mechanisms, including the induction of irreversible double-strand DNA breaks [27, 44] . We found that PAX4 blunts DNA damage in two models of experimental diabetes, pointing to a general protective mechanism, possibly through preserved ER homeostasis, implicating CALR [43] . The finding that PAX4overexpressing islets exhibited improved glucose-induced Ca 2+ oscillations points to this premise. Loss of oscillatory capacity is associated with diminished islet glucose sensitivity and increased ER dysfunction [45] . Thus, amplified Ca 2+ content in the CALR-enriched ER of PAX4overexpressing beta cells may impact cytosolic calcium dynamics [43, 46] , thereby preventing activation of downstream apoptotic pathways under stress conditions.
We conclude that PAX4 favours beta cell survival and regeneration in various deleterious inflammatory and highgrade inflammatory environments, such as autoimmunity, through the coordinated regulation of immune modulation, cell cycle, cell survival, ER homeostasis and DNA repair. While both PAX4 and PAX4R129W modulate these pathways, it is the wild-type transcription factor that conveys pro-survival properties by increasing the expression of selected adaptive genes. Fig. 8 PAX4-overexpressing islets exhibit normal calcium oscillation in response to glucose. Carbachol-stimulated (100 μmol/l) intracellular release of Ca 2+ was measured in intact islets (a) treated with DOX or (b) not treated. As indicated by the bars, islets were exposed to Ca 2+ -deficient medium containing 2 mmol/l EGTA prior to applying 100 μmol/l carbachol. (c) Analysis of the AUC for the time of the stimulus with carbachol from experiments shown in (a) and (b). (d) Analysis of the Ca 2+ peak amplitude in response to carbachol challenge. (n = 5-6). Representative Ca 2+ signals in response to 11 mmol/l glucose measured in intact islets (e) treated with DOX or (f) not treated. (g) Analysis of the AUC for the last 10 min of the glucose stimulus recording shown in (e) and (f). (h) Analysis of the amplitude of the first Ca 2+ transient in response to the glucose challenge. (i) Analysis of the basal fluorescence during the first minute of the experiments. n = 9; **p ≤ 0.01 and ***p ≤ 0.001. ΔF; fluorescence increase Access to research materials The raw data for the RNA microarray described herein are accessible in the Gene Expression Omnibus database under accession number GSE62846.
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